Products
Lutropin alfa is commercially available as an injectable (Luveris). It has been approved in many countries since 2002.
Structure and properties
Lutropin alfa is a is a recombinant human luteinizing hormone (LH). LH is a glycoprotein.
Indications
In combination with follicle-stimulating hormone (FSH) to stimulate follicular maturation in women with severe LH and FSH deficiency.
Dosage
According to the SmPC. The drug is injected subcutaneously.
Contraindications
For complete precautions, see the drug label.
Adverse effects
The most common possible adverse effects include:
- Abdominal pain, distended abdomen, nausea, vomiting, diarrhea.
- Dysuria.
- Upper respiratory tract infections.
- Headache, drowsiness, dizziness
- Reactions at the injection site, weakness, fever.
- Abdominal pain, breast pain, ovarian cysts, mild to moderate ovarian hyperstimulation syndrome.